Literature DB >> 26582734

[PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer].

Thibault Brotelle1, Jacques-Olivier Bay2.   

Abstract

Among many cancer cells signaling pathways, PI3K-AKT-mTOR plays a major role in growth, proliferation and cellular survival. This is a complex pathway activated either by an extracellular way (receptors with tyrosine kinase activity) or by an intracellular way with transformed or overexpressed proteins involved in the signal transduction. To date, there are many applications of mTOR inhibitors in oncology with an expanding development rapidly. However, resistances appear to mTOR inhibitors which lead to 2nd generation mTOR inhibitors development. A better knowledge of predictive and prognostic biomarkers will allow to specify the group of patients who may benefit from these treatments and help to the choice.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biomarker; Everolimus; Inhibiteur mTOR; Marqueur biologique; PI3K-AKT-mTOR; Resistance; Résistance; Temsirolimus; mTOR inhibitor; Évérolimus

Mesh:

Substances:

Year:  2015        PMID: 26582734     DOI: 10.1016/j.bulcan.2015.09.011

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  13 in total

1.  The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.

Authors:  Lan Deng; Ling Jiang; Xiang-Hua Lin; Kuo-Fu Tseng; Yuan Liu; Xing Zhang; Rui-Hong Dong; Zhi-Gang Lu; Xiu-Ju Wang
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

2.  KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.

Authors:  Ken Fujimura; Huawei Wang; Felicia Watson; Richard L Klemke
Journal:  Cancer Res       Date:  2018-01-10       Impact factor: 12.701

3.  β-elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation.

Authors:  Bo Cai; Limin Ma; Shaojun Nong; You Wu; Xin Guo; Jinxian Pu
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

4.  High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Wei Xi; Li Liu; Jiajun Wang; Yu Xia; Qi Bai; Qilai Long; Yiwei Wang; Jiejie Xu; Jianming Guo
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

5.  Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.

Authors:  Rui Zhang; Zhi Chen; Shu-Sheng Wu; Jun Xu; Ling-Chun Kong; Pei Wei
Journal:  Med Sci Monit       Date:  2019-06-01

6.  Cordycepin-induced unfolded protein response-dependent cell death, and AKT/MAPK-mediated drug resistance in mouse testicular tumor cells.

Authors:  Ming-Min Chang; Bo-Syong Pan; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Med       Date:  2019-05-30       Impact factor: 4.452

7.  Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase® the WHO Global Database of Individual Case Safety Reports.

Authors:  Alexandre Crosnier; Chadi Abbara; Morgane Cellier; Laurence Lagarce; Marina Babin; Delphine Bourneau-Martin; Marie Briet
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

Review 8.  mTOR signaling-related MicroRNAs and Cancer involvement.

Authors:  Ping Wang; Xiao-Min Liu; Lei Ding; Xin-Ju Zhang; Zhong-Liang Ma
Journal:  J Cancer       Date:  2018-01-08       Impact factor: 4.207

Review 9.  PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.

Authors:  Rui Liu; Youwen Chen; Guangzhi Liu; Chenxi Li; Yurong Song; Zhiwen Cao; Wen Li; Jinghong Hu; Cheng Lu; Yuanyan Liu
Journal:  Cell Death Dis       Date:  2020-09-24       Impact factor: 8.469

10.  Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway.

Authors:  Danning Shi; Hongbo Li; Zeye Zhang; Yueshuang He; Meng Chen; Liping Sun; Piwen Zhao
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.